XINGANJIANG
873167
INNOVATIVE DATA
835305
CHENGUANG MEDICAL
430300
4
Hangzhou Gaoxin Materials Technology
300478
5
Beijing Philisense Technology
300287
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | -11.64%3.04B | -4.84%1.2B | -2.88%1.01B | -25.44%513M | -30.25%309M | 6.71%3.44B | 21.02%1.26B | -0.29%1.04B | 2.99%688M | -4.32%443M |
Net income from continuing operations | 3.50%2.72B | 44.77%734M | -23.98%355M | -6.43%538M | 1.30%1.09B | -0.68%2.63B | -23.87%507M | 11.72%467M | 11.87%575M | 2.96%1.08B |
Operating gains losses | -8,325.00%-337M | ---4M | ---76M | ---- | ---- | 92.59%-4M | ---- | ---- | ---- | ---- |
Depreciation and amortization | 167.97%686M | 246.27%232M | 256.45%221M | 170.31%173M | -4.76%60M | -3.03%256M | 8.06%67M | -12.68%62M | -1.54%64M | -4.55%63M |
Deferred tax | 16.62%-311M | -17.02%-165M | 62.50%-24M | 53.06%-46M | -8.57%-76M | -48.02%-373M | 14.55%-141M | -25.49%-64M | -444.44%-98M | -288.89%-70M |
Other non cash items | -578.57%-134M | ---8M | ---14M | ---30M | ---82M | -83.53%28M | --0 | --0 | ---- | ---- |
Change In working capital | -113.64%-63M | -58.32%298M | -9.52%437M | -10.00%18M | -7.94%-816M | 862.50%462M | 227.98%715M | -7.29%483M | -45.95%20M | -3.85%-756M |
-Change in receivables | -65.96%-312M | -29.41%72M | 38.89%575M | -232.50%-133M | -24.40%-826M | -95.83%-188M | 104.00%102M | -21.59%414M | 69.23%-40M | -22.06%-664M |
-Change in payables and accrued expense | 2,923.08%393M | 15.95%429M | 36.08%215M | 227.78%92M | 22.57%-343M | 159.09%13M | 58.80%370M | 3.27%158M | -275.61%-72M | 1.34%-443M |
-Change in other current liabilities | -82.83%17M | -126.26%-26M | ---18M | --27M | --34M | --99M | --99M | --0 | --0 | --0 |
-Change in other working capital | -129.93%-161M | -222.92%-177M | -276.40%-335M | -75.76%32M | -9.12%319M | 224.10%538M | 321.54%144M | 44.38%-89M | 4.76%132M | 32.45%351M |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | -11.64%3.04B | -4.84%1.2B | -2.88%1.01B | -25.44%513M | -30.25%309M | 6.71%3.44B | 21.02%1.26B | -0.29%1.04B | 2.99%688M | -4.32%443M |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | -1,406.91%-2.83B | -140.42%-577M | 138.16%29M | 3,575.32%2.68B | -2,520.00%-4.96B | 58.13%-188M | 0.00%-240M | 9.52%-76M | -155.80%-77M | 177.95%205M |
Capital expenditure reported | 13.49%-218M | -12.24%-55M | -6.90%-62M | 23.19%-53M | 36.84%-48M | -28.57%-252M | 30.00%-49M | 0.00%-58M | -53.33%-69M | -230.43%-76M |
Net business purchase and sale | -9,253.33%-2.81B | -3,600.00%-481M | 1,130.00%103M | -41,550.00%-2.5B | 7,200.00%71M | 62.96%-30M | -85.71%-13M | -121.28%-10M | 33.33%-6M | 99.11%-1M |
Net investment purchase and sale | 103.19%191M | 76.97%-41M | -50.00%-12M | 261,500.00%5.23B | -1,867.38%-4.98B | 154.65%94M | -9.20%-178M | 89.04%-8M | -101.04%-2M | 320.31%282M |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | -1,406.91%-2.83B | -140.42%-577M | 138.16%29M | 3,575.32%2.68B | -2,520.00%-4.96B | 58.13%-188M | 0.00%-240M | 9.52%-76M | -155.80%-77M | 177.95%205M |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | 127.78%796M | 53.79%-769M | 39.85%-699M | -576.52%-3B | 1,202.23%5.26B | -60.06%-2.87B | -14.68%-1.66B | -284.77%-1.16B | 17.50%-443M | -19.20%404M |
Net issuance payments of debt | 555.86%2.41B | 51.46%-50M | -864.91%-550M | -5,227.27%-2.34B | 837.13%5.35B | -73.82%367M | 26.43%-103M | -111.88%-57M | -130.99%-44M | -37.93%571M |
Net common stock issuance | 64.95%-921M | 75.44%-182M | 67.56%-266M | 54.24%-248M | 57.14%-225M | 16.44%-2.63B | -11.26%-741M | 30.33%-820M | -9.05%-542M | 34.78%-525M |
Cash dividends paid | -14.93%-562M | -18.70%-146M | -17.60%-147M | -15.87%-146M | -6.96%-123M | -5.62%-489M | -6.03%-123M | -5.93%-125M | -5.88%-126M | -4.55%-115M |
Net other financing activities | -11.30%-128M | 43.90%-391M | 265.00%264M | -196.28%-259M | -45.45%258M | -127.64%-115M | -31.76%-697M | -131.19%-160M | 526.98%269M | -4.44%473M |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | 127.78%796M | 53.79%-769M | 39.85%-699M | -576.52%-3B | 1,202.23%5.26B | -60.06%-2.87B | -14.68%-1.66B | -284.77%-1.16B | 17.50%-443M | -19.20%404M |
Net cash flow | ||||||||||
Beginning cash position | 9.13%7.72B | 12.42%9.04B | -2.09%8.32B | -0.01%8.19B | 9.13%7.72B | 6.49%7.08B | 11.80%8.04B | 18.19%8.5B | 12.21%8.19B | 6.49%7.08B |
Current changes in cash | 161.26%998M | 77.29%-146M | 275.90%343M | 14.29%192M | -42.11%609M | -61.02%382M | 0.92%-643M | -129.55%-195M | -37.55%168M | 50.29%1.05B |
Effect of exchange rate changes | -246.59%-387M | -275.70%-564M | 245.77%379M | -138.62%-56M | -351.72%-146M | 148.09%264M | -39.43%321M | 60.37%-260M | 138.87%145M | 216.00%58M |
End cash Position | 7.91%8.33B | 7.91%8.33B | 12.42%9.04B | -2.09%8.32B | -0.01%8.19B | 9.13%7.72B | 9.13%7.72B | 11.80%8.04B | 18.19%8.5B | 12.21%8.19B |
Free cash flow | -11.50%2.82B | -5.53%1.15B | -3.45%951M | -25.69%460M | -28.88%261M | 5.29%3.18B | 24.69%1.21B | -0.30%985M | -0.64%619M | -16.59%367M |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |